Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies
The Journal of Infectious Diseases · 17.01.2026 · 233 (1) · e203-e211
DOI: 10.1093/infdis/jiaf533 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 24.10.2025. Verfasst von Stephanie Cox und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..
Abstract (Originalsprache)
Background
Lenacapavir (LEN) is an HIV-1 capsid inhibitor being evaluated for pre-exposure prophylaxis (PrEP). The PURPOSE trials assessed the efficacy of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) in cisgender women (PURPOSE 1; P1) and in cisgender men, transgender women, transgender men and gender non-binary persons (PURPOSE 2; P2). Emtricitabine/tenofovir alafenamide (F/TAF) was also assessed in P1. Both studies demonstrated the superiority of LEN to F/TDF. We describe resistance analyses from P1 and P2, which provide the first data regarding emergent drug resistance in the context of LEN for PrEP.
Methods
HIV testing was performed at screening, baseline, and every study visit. Participants who acquired HIV-1 with a viral load of ≥200 copies/mL were evaluated for resistance by genotyping of the HIV-1 capsid, protease, reverse transcriptase and integrase genes at HIV diagnosis. Adherence in the F/TDF and F/TAF groups was measured by dried blood spot.
Results
Resistance to LEN was detected in 0 of 2134 participants (P1) and 2 of 2179 participants (P2); both developed N74D. Four participants in each study receiving LEN were found to have unrecognized HIV-1 at baseline; 4/8 participants developed N74D. In P1, 2/37 participants analyzed for resistance in the F/TAF group had M184I ± K65R. In the F/TDF groups, M184M/I/V was detected in 1/16 participants (P1) and 1/9 participants (P2).
Conclusions
Acquisition of HIV while receiving LEN and resistance to LEN in the context of unrecognized HIV was rare but associated with the emergence of the N74D LEN resistance-associated substitution in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, USA.
ORCID-Profile: Stephanie Cox, Kristen Andreatta, Matthew R Hendricks, Jiani Li, Alexander Kintu, Lillian B Brown, Christoph C Carter, Christian Callebaut
Förderung
- Gilead Sciences, Inc.
Zitieren
APA
Cox, S., Andreatta, K., Hendricks, M. R., Li, J., Kintu, A., Brown, L. B., Carter, C. C., & Callebaut, C. (2026). Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. The Journal of Infectious Diseases, 233(1), e203-e211. https://doi.org/10.1093/infdis/jiaf533
Vancouver
Cox S, Andreatta K, Hendricks MR, Li J, Kintu A, Brown LB, et al. Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. The Journal of Infectious Diseases. 2026;233(1):e203-e211. doi:10.1093/infdis/jiaf533
BibTeX
@article{Cox2026,
author = {Cox, Stephanie and Andreatta, Kristen and Hendricks, Matthew R and Li, Jiani and Kintu, Alexander and Brown, Lillian B and Carter, Christoph C and Callebaut, Christian},
title = {Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {1},
pages = {e203--e211},
doi = {10.1093/infdis/jiaf533}
}
EUVIMED